Human Immunodeficiency Virus (HIV) - US Drug Forecast and Market Analysis to 2023
"Human Immunodeficiency Virus (HIV) - US Drug Forecast and Market Analysis to 2023" . The Report covers current Market Trends, Analysis, Forecast, Review, Share, Size, Growth, Effect. Description- Summary Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKlines (GSKs) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science's Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level of convenience. To Free Sample Report With TOC @ http:/